Retatrutide, a triple GIP/GLP-1/glucagon receptor agonist, provides robust HbA1c and body weight reductions to people with type 2 diabetes: a 36--week, phase 2 study - Coskun, Tamer; Rosenstock, Julio; Frias, Juan; Jastreboff, Ania M.; Du, Yu; Lou, Jitong; Gurbuz, Sirel; Hartman, Mark L.; Haupt, Axel; Milicevic, Zvonko; Seufert, Jochen (Diabetologie und Stoffwechsel, 2024)